The objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Each eligible subject is treated with DAS181 for 10 days and observed for 28 days from the first day of administration. From day 1 to 10, once or twice a day, for 10 consecutive days, a total of 9 mg (7 ml) nebulized DAS181 is given. If DAS181 is given by twice a day, one vial containing 4.5 mg (3.5m1) DAS181 should be delivered with about 12-hour interval.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
4
Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Improved clinical status
Percent of subjects with improved clinical status
Time frame: Day 14
Return to room air
Percent of subjects return to room air
Time frame: Day 14
SARS-CoV-2 RNA
time to SARS-CoV-2 RNA in the respiratory specimens being undetectable
Time frame: 28 days
Discharge
Percent of patients discharge from hospital
Time frame: Days 14, 21, 28
Death
All-cause mortality rate
Time frame: Day 14, 21, 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.